← All trials
NCT03037151
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2017
- Primary completion
- Jan 19, 2022
- Completion date
- Jan 19, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- The HIV Netherlands Australia Thailand Research CollaborationLead sponsor
- Chulalongkorn UniversityOverall official - principal investigator
- HIV-NAT Thai Red Cross AIDS Research CenterOverall official - principal investigator
- Chulalongkorn UniversityCollaborator
- MerckCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.